NEWS

JOB LISTINGS

CONNECT WITH US

	Become a fan on Facebook
	Add us on Google Plus
	Follow us on Twitter
	Join us on LinkedIn
	Sign up for our Newsletters
	Subscribe to our RSS Feed

Melanoma

Women Have a 30% Survival Advantage in Melanoma

RESEARCH REPORT
Dave Levitan
A new analysis of four large European trials of cutaneous melanoma patients showed a substantial survival advantage for women, most likely explained by underlying biologic differences. The study included pooled results from four European Organisation for Research and Treatment of Cancer trials comprising 2,672 patients with stage I/II melanoma. The study results were published recently in the Journal of Clinical Oncology.
Sorafenib Doesn't Improve Response to Isolated Limb Infusion in Extremity Melanoma

RESEARCH REPORT
Dave Levitan
The addition of sorafenib to isolated limb infusion therapy with melphalan did not improve responses in a new phase I trial of patients with in-transit extremity melanoma.
PREX2, New Melanoma Mutation Identified

RESEARCH REPORT
Anna Azvolinsky
The identification of a driver mutation in the BRAF gene found in approximately 40% of metastatic melanoma patients and the subsequent approval last year of the targeted BRAF inhibitor, vemurafenib, has resulted in a surge of both clinical and laboratory research. Researchers have been actively analyzing the mechanisms of resistance to BRAF inhibitors, attempting to identify the next-generation therapies and novel combination treatments to stop further cancer progression.
In-Transit Melanoma: An Individualized Approach

REVIEW ARTICLE
Travis E. Grotz, Aaron S. Mansfield, et al; ONCOLOGY Vol. 25 No. 14
The management of in-transit metastases is challenging, since the treatments and extent of disease vary greatly based on the number, depth, location, and distribution of lesions, and on their biological behavior.
• Treatment of In-Transit Melanoma
• Individualized Local Treatment Strategies for In-Transit Melanoma
Metastasectomy in Melanoma and Breast Cancer

REVIEW ARTICLE
Sabino Zani, Bryan M. Clary; ONCOLOGY Vol. 25 No. 12
This review summarizes the existing literature that addresses the topic of metastasectomy in patients with melanoma and breast cancer.
• Hepatic Metastasectomy for Breast Cancer and Melanoma
• The Role of Hepatic Metastasectomy in Melanoma and Breast Cancer

REVIEW ARTICLES

In-Transit Melanoma: An Individualized Approach
Travis E. Grotz, MD¹, Aaron S. Mansfield, MD^2,3, Lisa A. Kottschade, CNP^2,3, Lori A. Erickson, MD⁴, Lori A. Erickson, MD⁵, Svetomir N. Markovic, MD, PhD^2,3, James W. Jakub, MD¹ , December 30, 2011

The management of in-transit metastases is challenging, since the treatments and extent of disease vary greatly based on the number, depth, location, and distribution of lesions, and on their biological behavior.
• In-Transit Melanoma: Opportunity to Discover Critical Knowledge
• Individualized Local Treatment Strategies for In-Transit Melanoma

A Role for Hepatic Metastasectomy in Stage IV Melanoma and Breast Cancer: Reestablishing the Surgical Modality
Sabino Zani, MD¹, Bryan M. Clary, MD¹ , November 15, 2011

With the potential for therapeutic durability and a small chance of cure, surgical resection may offer improved survival compared to other therapeutic modalities. This review summarizes the existing literature that addresses the topic of metastasectomy in patients with melanoma and breast cancer.
• Hepatic Metastasectomy for Breast Cancer and Melanoma
• The Role of Hepatic Metastasectomy in Melanoma and Breast Cancer

Ipilimumab: A Promising Immunotherapy for Melanoma
Jaykumar R. Thumar, MD¹, Harriet M. Kluger, MD² , January 5, 2011

This marks the first randomized clinical trial reporting an overall survival benefit using immune modulation in metastatic melanoma. Along with its therapeutic benefits, ipilimumab presents unique challenges to clinicians.
• CTLA-4–Blocking Immunotherapy With Ipilimumab for Advanced Melanoma
• Ipilimumab for Advanced Melanoma: Let’s Not Throw Caution to the Winds
• Improving the Therapeutic Benefits of Ipilimumab

Your Patient With Melanoma: Staging, Prognosis, and Treatment
Krista M. Rubin, MS, RN, FNP-BC¹, Donald P. Lawrence, MD² , August 5, 2009

This article will review diagnosis, staging, and treatment for malignant melanoma and will discuss the nursing role in the care of patients with melanoma.
• Melanoma: An Under-recognized Cancer Threat

Treatment of Metastatic Melanoma: An Overview
Shailender Bhatia, MD¹, Scott S. Tykodi, MD, PhD², John A. Thompson, MD³ , May 12, 2009

This article article reviews the treatments for metastatic melanoma including promising investigational approaches.
• The Pathway Ahead in Melanoma Trials
• Treating Metastatic Melanoma: Further Considerations
• The Future of Melanoma Therapy Appears Bright

IMAGE IQ

A 67-Year-Old African American Woman Presents With a Lesion on the Right Leg
February 27, 2012

A 67-year-old African American female presented with an approximately 18-month history of a solitary, asymptomatic lesion on the right leg. This patient most likely has what tumor on her leg?

A 68-Year-Old Woman Presents With Scalp Mass, Biopsy Reveals Basal Cell Carcinoma
February 6, 2012

A 68-year-old woman presented with a mass on the scalp which had been present for approximately 7 years. An incisional biopsy of the scalp mass and excisional biopsy of the lymph node both revealed basal cell carcinoma, micronodular histologic subtype.

Image IQ: A 29-Year-Old Man Presents With Stage IV, Poorly Differentiated Malignant Melanoma
November 21, 2011

A 29-year-old man was presented early in this series as an example of stage IV, poorly differentiated malignant melanoma. As noted previously, evaluation disclosed the presence of multifocal metastatic disease (lungs, lymph nodes).